April 27 (Reuters) – Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
(Reporting by Kunal Das; Editing by Vijay Kishore)
April 27 (Reuters) – Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
(Reporting by Kunal Das; Editing by Vijay Kishore)
Comments